Compare Avient Corporation (AVNT) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avient Corporation vs Quest Diagnostics Inc — how do they compare? Avient Corporation trades at $45.19 (market cap $4.17B), while Quest Diagnostics Inc trades at $237.14 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 6.3× Avient Corporation's market cap, and Avient Corporation pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| AVNT | DGX | |
|---|---|---|
Market Cap | $4.17B | $26.21B |
Sector | Technology | Health |
52-Week High | $45.69 | $238.50 |
52-Week Low | $27.48 | $173.49 |
Enterprise Value | $5.62B | $31.97B |
Dividend Yield | 2.42% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Avient (AVNT) trades at $45.1, down 1.2% today, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings of $0.96 per share, beating estimates, and has consistently exceeded expectations in recent quarters. Revenue remains stable at $3.3 billion, with a net income margin improving to 5.1% in 2026. Analysts maintain a Buy consensus with a $49 price target, reflecting optimism about continued growth and dividend stability.
The stock offers upside potential from earnings momentum and a solid dividend yield, but faces risks from macroeconomic pressures on materials demand and high RSI levels suggesting overbought conditions. Institutional sentiment is positive, with no Sell ratings, though investors should monitor debt levels and competitive dynamics in the chemical sector for sustained performance.
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
